FDA Approves Xenleta (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)
DUBLIN, Ireland, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 19, 2019 Category: Drugs & Pharmacology Source Type: news
FDA approves new antibiotic to treat community-acquired bacterial pneumonia
The FDA approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 19, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
New Antibiotic Xenleta Approved for Community-Acquired Bacterial Pneumonia
MONDAY, Aug. 19, 2019 -- Xenleta (lefamulin) has been approved to treat adults with community-acquired bacterial pneumonia, the U.S. Food and Drug Administration announced today.
Dosing of Xenleta is either an oral administration of 600 mg every 12... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 19, 2019 Category: General Medicine Source Type: news
Practical Tips for Diagnosing and Treating Bacterial Pneumonia in the Nursing Home
A clinical diagnosis of bacterial pneumonia in nursing home residents most often can be treated with a single oral course of antibiotic therapy targeted toward community-acquired pneumonia pathogens, Ghinwa Dumyati, MD, said at the AMDA — The Society for Post-Acute and Long-Term Care Medicine’s annual conference. (Source: Caring for the Ages)
Source: Caring for the Ages - July 30, 2019 Category: Health Management Authors: Christine Kilgore Source Type: news
Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia
TUESDAY, June 11, 2019 -- Zerbaxa (ceftolozane and tazobactam) has been approved for a new indication to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older, the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 11, 2019 Category: General Medicine Source Type: news
FDA expands Merck antibiotic indication to pneumonia treatment
The previously FDA-approved drug, Zerbaxa, is now indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 4, 2019 Category: Pharmaceuticals Source Type: news
Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia
TUESDAY, June 4, 2019 -- Zerbaxa (ceftolozane and tazobactam) has been approved for a new indication to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older, the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2019 Category: Pharmaceuticals Source Type: news
FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia
FDA today approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 4, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Dual Antibiotic Zerbaxa Gets FDA Nod for Bacterial Pneumonia Dual Antibiotic Zerbaxa Gets FDA Nod for Bacterial Pneumonia
Zerbaxa (ceftolozane and tazobactam) for hospital- and ventilator-associated bacterial pneumonia was initially approved for complicated intra-abdominal and urinary tract infections.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 4, 2019 Category: Drugs & Pharmacology Tags: Pulmonary Medicine News Alert Source Type: news
FDA Approves Zerbaxa (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Monday, June 3, 2019 -- KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Merck’s supplemental New Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 3, 2019 Category: Drugs & Pharmacology Source Type: news
Merck wins U.S. FDA approval for expanded use of antibiotic
The U.S. Food and Drug Administration said https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia on Monday it approved expanded use of Merck& Co Inc's antibiotic to treat hospital-acquired pneumonia in patients 18 years and older. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Characteristics and Outcomes of Patients With and Without Type 2 Diabetes Mellitus and Pulmonary Sepsis
To date, studies have provided conflicting results regarding the impact of type 2 diabetes mellitus (DM) on sepsis-related outcomes. Our objective is to understand the impact of type 2 DM in bacterial pneumonia and sepsis-related intensive care unit (ICU) outcomes. Our findings demonstrated that type 2 DM does not increase the overall mortality. Our findings of increased mortality in both type 2 DM patients with lower admission glucose, and non-DM patients with higher mean glucose during the hospital stay needs to be further evaluated. Future studies in regards to this could lead to personalized glucose treatment g...
Source: Current Awareness Service for Health (CASH) - April 25, 2019 Category: Consumer Health News Source Type: news
Omadacycline Found Similar to Usual Care for CABP, ABSSSI (CME/CE)
(MedPage Today) -- Well-tolerated option for select patients with community-acquired bacterial pneumonia and skin infections (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - February 13, 2019 Category: Infectious Diseases Source Type: news
Omadacycline Noninferior to Moxifloxacin for Pneumonia
WEDNESDAY, Feb. 6, 2019 -- Omadacycline is noninferior to moxifloxacin for community-acquired bacterial pneumonia and noninferior to linezolid for acute bacterial skin infections, according to two studies published in the Feb. 7 issue of the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 6, 2019 Category: Pharmaceuticals Source Type: news
Second Child In Mass. Dies From Flu-Related Illness
BOSTON (CBS) — A four-year-old girl from Framingham has died from a flu-related illness, the second flu-related death of a child in Massachusetts this week, the Framingham Public Health Department announced Friday.
According to the DPH, the cases are unrelated “and were confirmed by the DPH’s State Public Health Laboratory.”
The death of a 12-year-old boy from Milford with a flu-related illness was announced Thursday.
The boy’s mother told WBZ-TV he got his flu shot this year, but still got sick. He stayed home from school for multiple days until he developed a bacterial infection and was rush...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 1, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Seen On WBZ-TV Syndicated Local Flu Flu Deaths Local TV Source Type: news
